Mepazine (C007B-582085)

Mepazine (Pecazine) is a potent and selective MALT1 protease inhibitor with IC 50 s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine affects viability of ABC-DLBCL cells by enhancing apoptosisIn VitroMepazine (5-20 μM; 4 days) causes a decrease of cell viability in the activated B cell subtype of diffuse large B cell lymphoma (ABCDLBCL) cells, without significantly affecting GCB-DLBCL cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: ABC-DLBCL cell lines (HBL1, OCI-Ly3, U2932, TMD8, OCI-Ly10) and GCB-DLBCL cell lines (BJAB, Su-DHL-6, Su-DHL-4) Concentration: 5, 10, and 20 μM Incubation Time: 4 days Result: Caused a decrease of cell viability in the ABC-DLBCL cells HBL1, OCI-Ly3, U2932, and TMD8, without significantly affecting GCB-DLBCL cells.In VivoMepazine (16 mg/kg; intraperitoneal administration) interferes with growth and induces apoptosis of ABC-DLBCL cell line OCI-Ly10 in NOD/scid IL-2Rg (NSG) mice with a murine DLBCL xenogeneic tumor model. Daily administration of Mepazine strongly impairs the expansion of the ABC-DLBCL cell line OCI-Ly10 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6- to 8-week-old female NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice with a murine DLBCL xenogeneic tumor model Dosage: 400 μg per animal (25 g), corresponding to approximately 16 mg/kg. Administration: Intraperitoneal administration; started 1 or 12 days after transplantation and given continuously every 24 hr; daily application Result: Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10.

Specifictaions: Moligand™, ≥98%

MDL Number: C19H22N2S

Molecular Formula: 310.46

PubChem CID: 6075

Isomeric SMILES: CN1CCCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42